NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Clinical trials for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION explained in plain language.
Never miss a new study
Get alerted when new NEOVASCULAR AGE-RELATED MACULAR DEGENERATION trials appear
Sign up with your email to follow new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
One-shot gene therapy aims to free patients from endless eye injections
Disease control OngoingThis study is observing the long-term safety and effectiveness of a one-time gene therapy injection for wet age-related macular degeneration (AMD), a leading cause of blindness. It follows 23 people for up to 10 years after they received the therapy in a previous trial. The goal …
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Sponsor: Adverum Biotechnologies, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
Eye injection showdown: which treatment lasts longer?
Disease control OngoingThis study compares two similar eye injection treatments for wet age-related macular degeneration, a leading cause of vision loss in older adults. Researchers want to see if one treatment (bevacizumab) requires more frequent injections than the other (aflibercept) to maintain the…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Phase: PHASE2 • Sponsor: Vastra Gotaland Region • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
New eye injection enters human testing to fight leading cause of blindness
Disease control OngoingThis is the first study in people testing a new drug called ASKG712, given as an injection into the eye, for wet age-related macular degeneration (AMD). The main goal is to find out if different doses are safe and how the body processes the drug. Researchers will also check if th…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Phase: PHASE1 • Sponsor: AskGene Pharma, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:27 UTC
-
New High-Dose eye shot tested for common Vision-Threatening conditions
Disease control OngoingThis study is testing a higher dose of an existing eye injection medicine (aflibercept 8 mg) for people with wet age-related macular degeneration (AMD) or diabetic macular edema (DME). It aims to see if this higher dose is safe and effective when given as often as once a month. T…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Mar 19, 2026 14:56 UTC
-
One-Shot gene therapy could reduce eye injections for millions
Disease control OngoingThis study is testing whether a single gene therapy injection (LX102) can help control wet age-related macular degeneration, potentially reducing the need for frequent eye injections. It compares two doses of the experimental therapy against the current standard treatment in 50 p…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Phase: PHASE2 • Sponsor: Innostellar Biotherapeutics Co.,Ltd • Aim: Disease control
Last updated Mar 13, 2026 15:06 UTC
-
Massive 6,000-Patient study tracks Long-Term eye treatment results
Knowledge-focused OngoingThis study aims to collect long-term, real-world information on how patients with serious eye conditions like macular degeneration and diabetic eye swelling respond to specific Roche eye injection treatments. It will observe 6,000 patients already receiving these approved treatme…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Sponsor: Hoffmann-La Roche • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:31 UTC